Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

This study has been completed.
Sponsor:
Collaborator:
Ortho Biotech Clinical Affairs, L.L.C.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT00388336
First received: October 13, 2006
Last updated: May 17, 2011
Last verified: April 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2005
  Estimated Primary Completion Date: No date given